Bookmark

Add to MyYahoo RSS

Threshold Pharmaceuticals News

News on Threshold Pharmaceuticals (Ticker: THLD) continually updated from thousands of sources around the net.

Friday Aug 1 | Sys-Con Media

Threshold Pharmaceuticals Reports Second Quarter 2014 Financial and Operational Results

Revenue for the second quarter ended June 30, 2014 was $3.7 million. The operating loss for the second quarter ended June 30, 2014 was $7.5 million.

Comment?

Related Topix: Startups, Sarcoma, Medicine, World News, Germany

Wed Jul 09, 2014

Benzinga

Threshold Announces Initiation Of Dosing With TH-302/Bortezomib In...

Threshold Pharmaceuticals, Inc. today announced that dosing has started in the final stage of an ongoing Phase 1/2 trial of its investigational hypoxia-activated prodrug, TH-302, in combination with the proteasome inhibitor bortezomib and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma, a cancer of the bone marrow.

Comment?

Related Topix: Startups, Cancer, Medicine, Health, Oncology

Tue Jul 08, 2014

AmericanBankingNews.com

Threshold Pharmaceuticals Coverage Initiated by Analysts at Brean Capital

The firm set a "buy" rating and a $15.00 price target on the stock. Brean Capital's price target would indicate a potential upside of 265.85% from the stock's previous close.

Comment?

Related Topix: Startups

Mon Jul 07, 2014

Seeking Alpha

Threshold Initiates Phase 2 Clinical Trial In Advanced Non-Squamous Non-Small Cell Lung Cancer

Threshold initiated a Phase 2 trial with TH-302 for the treatment of advanced non-squamous non-small cell lung carcinoma .

Comment?

Related Topix: Healthcare Law, Law, Health, Lung Cancer, Biotech, Medicine, Merck KGaA, Healthcare Industry, Startups, Pancreatic Cancer, Sarcoma

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••